You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 12, 2024

Glenmark Specialty Company Profile


✉ Email this page to a colleague

« Back to Dashboard


What is the competitive landscape for GLENMARK SPECIALTY, and when can generic versions of GLENMARK SPECIALTY drugs launch?

GLENMARK SPECIALTY has one approved drug.

There are fourteen US patents protecting GLENMARK SPECIALTY drugs.

There are eighty patent family members on GLENMARK SPECIALTY drugs in thirty-two countries and twelve supplementary protection certificates in eleven countries.

Summary for Glenmark Specialty
International Patents:80
US Patents:14
Tradenames:1
Ingredients:1
NDAs:1

Drugs and US Patents for Glenmark Specialty

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Glenmark Specialty RYALTRIS mometasone furoate; olopatadine hydrochloride SPRAY, METERED;NASAL 211746-001 Jan 13, 2022 RX Yes Yes 9,750,754 ⤷  Try a Trial Y ⤷  Try a Trial
Glenmark Specialty RYALTRIS mometasone furoate; olopatadine hydrochloride SPRAY, METERED;NASAL 211746-001 Jan 13, 2022 RX Yes Yes 9,078,923 ⤷  Try a Trial Y ⤷  Try a Trial
Glenmark Specialty RYALTRIS mometasone furoate; olopatadine hydrochloride SPRAY, METERED;NASAL 211746-001 Jan 13, 2022 RX Yes Yes 11,679,210 ⤷  Try a Trial Y ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for Glenmark Specialty Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
3043773 2022C/520 Belgium ⤷  Try a Trial PRODUCT NAME: MOMETASONE OF EEN ZOUT HIERVAN EN OLOPATADINE OF EEN ZOUT HIERVAN; AUTHORISATION NUMBER AND DATE: BE595626 20220203
3043773 C202130060 Spain ⤷  Try a Trial PRODUCT NAME: MOMETASONA O UNA SAL DE LA MISMA Y OLOPATADINA O UNA SAL DE LA MISMA; NATIONAL AUTHORISATION NUMBER: 86059-SE/H/2040/001/DC; DATE OF AUTHORISATION: 20210701; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): 140638; DATE OF FIRST AUTHORISATION IN EEA: 20210419
3043773 21C1057 France ⤷  Try a Trial PRODUCT NAME: MOMETASONE OU L'UN DE SES SELS AVEC OLOPATADINE OU L'UN DE SES SELS; NAT. REGISTRATION NO/DATE: NL52121 20211026; FIRST REGISTRATION: AT - 140638 20210426
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.